FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2341822171> ?p ?o ?g. }

• W2341822171 endingPage "S159" @default.
• W2341822171 startingPage "S158" @default.
• W2341822171 abstract "β-blocker medications have a favorable safety profile in adult heart failure patients. However, there are no long-term studies on utilization or safety of β-blockers in pediatric heart failure. Therefore, we aimed to describe dose ranges, adverse events, and changes in cardiac function in a well characterized population of children with dilated cardiomyopathy (DCM) treated with carvedilol. The Pediatric Cardiomyopathy Registry was used to identify patients who were treated with carvedilol from 1997 to 2005. The decision to treat was made by the local physician. The cohort included 118 patients (52% female, 58% white), median age at start of treatment was 4.4 years (interquartile range [IQR] 1.0-13.3) and median weight 18.2 kg (IQR 8.7-52.0). Most cases were idiopathic, (66%) with myocarditis (15%) and familial DCM (12%) as the most common identifiable causes. The majority (63%) had symptoms of heart with 95% on angiotensin converting enzyme inhibitor at carvedilol initiation. The median carvedilol dose at initiation was 0.16 mg/kg/day (IQR: 0.1-0.3) and the median maximal dose achieved was 0.5 mg/kg/day (IQR: 0.2-0.8). The median duration of carvedilol use was 361 days (IQR: 101-958) with 18% treated for > 3 years. Blood pressure was within normal limits for the majority of patients at all time points evaluated (>95% for systolic and >75% for diastolic). There were no episodes of 3rd degree heart block. Carvedilol was discontinued in 41 patients, mostly secondary to heart transplantation (61%) or resolution of cardiac disease (12%). There were 2 hospitalizations for bronchial reactivity and none for hypotension or bradycardia. Four patients stopped carvedilol secondary to an apparent side-effect. The shortening fraction increased from 16% ± 8 (median 16%, IQR: 10-22%) at carvedilol initiation (n=98) to 21% ± 9 (median 21%, IQR: 15-25%) at 1 year (n=49) (p=0.001), 23% ± 9 (median 22%, IQR: 16-28%) at 2 years (n=20) (p=0.04), and 22% ± 8 (median 22%, IQR: 16-30%) at 3 years (n=18) post-carvedilol initiation (p=0.04). Carvedilol was well tolerated in the majority of patients with up to 3 years of medication administration with evidence of reverse remodeling in survivors. Further study of the long term remodeling effects of β-blockers in pediatric heart failure is required." @default.
• W2341822171 created "2016-06-24" @default.
• W2341822171 creator A5000020632 @default.
• W2341822171 creator A5003497085 @default.
• W2341822171 creator A5009500329 @default.
• W2341822171 creator A5009577898 @default.
• W2341822171 creator A5013335511 @default.
• W2341822171 creator A5016884520 @default.
• W2341822171 creator A5020642145 @default.
• W2341822171 creator A5031349773 @default.
• W2341822171 creator A5035369958 @default.
• W2341822171 creator A5050865228 @default.
• W2341822171 creator A5058530779 @default.
• W2341822171 creator A5070476822 @default.
• W2341822171 creator A5070771799 @default.
• W2341822171 creator A5071852921 @default.
• W2341822171 creator A5082899595 @default.
• W2341822171 creator A5087071616 @default.
• W2341822171 creator A5090814913 @default.
• W2341822171 creator A5091091627 @default.
• W2341822171 date "2016-04-01" @default.
• W2341822171 modified "2023-10-01" @default.
• W2341822171 title "Utilization and Safety of Long-Term Carvedilol in Pediatric Dilated Cardiomyopathy: A Multicenter Study from the Pediatric Cardiomyopathy Registry" @default.
• W2341822171 doi "https://doi.org/10.1016/j.healun.2016.01.441" @default.
• W2341822171 hasPublicationYear "2016" @default.
• W2341822171 type Work @default.
• W2341822171 sameAs 2341822171 @default.
• W2341822171 citedByCount "0" @default.
• W2341822171 crossrefType "journal-article" @default.
• W2341822171 hasAuthorship W2341822171A5000020632 @default.
• W2341822171 hasAuthorship W2341822171A5003497085 @default.
• W2341822171 hasAuthorship W2341822171A5009500329 @default.
• W2341822171 hasAuthorship W2341822171A5009577898 @default.
• W2341822171 hasAuthorship W2341822171A5013335511 @default.
• W2341822171 hasAuthorship W2341822171A5016884520 @default.
• W2341822171 hasAuthorship W2341822171A5020642145 @default.
• W2341822171 hasAuthorship W2341822171A5031349773 @default.
• W2341822171 hasAuthorship W2341822171A5035369958 @default.
• W2341822171 hasAuthorship W2341822171A5050865228 @default.
• W2341822171 hasAuthorship W2341822171A5058530779 @default.
• W2341822171 hasAuthorship W2341822171A5070476822 @default.
• W2341822171 hasAuthorship W2341822171A5070771799 @default.
• W2341822171 hasAuthorship W2341822171A5071852921 @default.
• W2341822171 hasAuthorship W2341822171A5082899595 @default.
• W2341822171 hasAuthorship W2341822171A5087071616 @default.
• W2341822171 hasAuthorship W2341822171A5090814913 @default.
• W2341822171 hasAuthorship W2341822171A5091091627 @default.
• W2341822171 hasBestOaLocation W23418221711 @default.
• W2341822171 hasConcept C119060515 @default.
• W2341822171 hasConcept C126322002 @default.
• W2341822171 hasConcept C164705383 @default.
• W2341822171 hasConcept C197934379 @default.
• W2341822171 hasConcept C2776383484 @default.
• W2341822171 hasConcept C2778198053 @default.
• W2341822171 hasConcept C2778797674 @default.
• W2341822171 hasConcept C2778849806 @default.
• W2341822171 hasConcept C2780591200 @default.
• W2341822171 hasConcept C2780875844 @default.
• W2341822171 hasConcept C2908647359 @default.
• W2341822171 hasConcept C71924100 @default.
• W2341822171 hasConcept C99454951 @default.
• W2341822171 hasConceptScore W2341822171C119060515 @default.
• W2341822171 hasConceptScore W2341822171C126322002 @default.
• W2341822171 hasConceptScore W2341822171C164705383 @default.
• W2341822171 hasConceptScore W2341822171C197934379 @default.
• W2341822171 hasConceptScore W2341822171C2776383484 @default.
• W2341822171 hasConceptScore W2341822171C2778198053 @default.
• W2341822171 hasConceptScore W2341822171C2778797674 @default.
• W2341822171 hasConceptScore W2341822171C2778849806 @default.
• W2341822171 hasConceptScore W2341822171C2780591200 @default.
• W2341822171 hasConceptScore W2341822171C2780875844 @default.
• W2341822171 hasConceptScore W2341822171C2908647359 @default.
• W2341822171 hasConceptScore W2341822171C71924100 @default.
• W2341822171 hasConceptScore W2341822171C99454951 @default.
• W2341822171 hasIssue "4" @default.
• W2341822171 hasLocation W23418221711 @default.
• W2341822171 hasOpenAccess W2341822171 @default.
• W2341822171 hasPrimaryLocation W23418221711 @default.
• W2341822171 hasRelatedWork W116719894 @default.
• W2341822171 hasRelatedWork W1732323254 @default.
• W2341822171 hasRelatedWork W2113205822 @default.
• W2341822171 hasRelatedWork W2116087702 @default.
• W2341822171 hasRelatedWork W2374022257 @default.
• W2341822171 hasRelatedWork W2402738988 @default.
• W2341822171 hasRelatedWork W2410456140 @default.
• W2341822171 hasRelatedWork W3035006171 @default.
• W2341822171 hasRelatedWork W3103526587 @default.
• W2341822171 hasRelatedWork W2182973013 @default.
• W2341822171 hasVolume "35" @default.
• W2341822171 isParatext "false" @default.
• W2341822171 isRetracted "false" @default.
• W2341822171 magId "2341822171" @default.
• W2341822171 workType "article" @default.